Roquin

Quick links to important sections

Roquin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roquin

Quick Facts

Property Description
Active ingredient Chloroquine Phosphate
Form Tablet (Oral preparation)
Pharmacological class Antimalarial / Antirheumatic Agent
General purpose Anti-parasitic action and immune system modulation
Origin Synthetic drug (4-aminoquinoline class)

What is Roquin: Definition and Pharmacological Class

Roquin is a synthetic drug classified primarily as a 4-aminoquinoline derivative that holds a dual designation as both an antimalarial agent and an antirheumatic agent. This dual classification reflects its unique pharmacological scope; for instance, Chloroquine is recognized on essential medicine lists, confirming its established importance in global public health for parasitic disease management. Its secondary role as a Disease-Modifying Antirheumatic Drug (DMARD) suggests an ability to modulate underlying chronic immune conditions, distinguishing it from simpler symptom-relieving agents.


Composition, Origin, and Physical Form

The active ingredient in Roquin is Chloroquine, commonly supplied as Chloroquine Phosphate, a substance that confirms its entirely synthetic origin. Chloroquine is a single-ingredient compound derived from the quinoline structure. The medicine is presented as a tablet intended for oral administration, meaning the active substance is ingested to achieve a systemic effect throughout the body. The form ensures reliable delivery of the Chloroquine compound into the digestive system for subsequent absorption.


General Purpose of this 4-Aminoquinoline Compound

The overarching function of Roquin is to exert an antiprotozoal action and an immunomodulatory effect on the body. This combination of effects provides the general therapeutic benefit of either intervening in the life cycle of parasitic invaders, or by helping to stabilize and reduce a misdirected inflammatory response in conditions driven by the immune system. Chloroquine and its derivatives are recognized for their ability to affect the immune response through complex cellular mechanisms. This dual utility ensures its continued relevance across different areas of medicine.

Regulatory References

  1. NIH Review of Chloroquine Immunomodulatory Effects
  2. Chloroquine Immunomodulatory Review (NIH)

What side effects are possible with Roquin?

System-Specific Adverse Reactions

The official safety profile for Roquin (Chloroquine Phosphate) details adverse reactions categorized by the body system affected, a classification standard used by regulatory agencies. Documented reactions involve Ocular (eye) disorders, Cardiac (heart) issues, Nervous System effects, Gastrointestinal symptoms, and Skin and Blood disorders.

Frequency of Adverse Effects

Adverse effects are categorized by frequency, though classifications can vary between regulatory labels. Very Common or frequently reported effects include nausea, vomiting, abdominal pain, and headache. Less common reactions include retinopathy, dizziness, diarrhea, and certain skin changes. Other serious effects, such as severe cutaneous reactions, ventricular arrhythmias, and suicidal behavior, are documented but often categorized as Not Known or Rare based on postmarketing reports.

Serious Safety Considerations

The labeling explicitly notes the risk of serious adverse reactions. These include irreversible retinal damage (retinopathy), fatal cardiomyopathy (heart muscle disease), and life-threatening ventricular arrhythmias (abnormal heart rhythms, like Torsades de pointes). Other serious reported events include severe hypoglycemia, aplastic anemia, and acute extrapyramidal disorders.

Population and Duration-Related Safety

Safety statements indicate that the risk of irreversible ocular damage is linked to the cumulative dosage and duration of treatment. Caution is noted for pediatric patients due to their increased sensitivity to the compound. Similarly, caution is necessary in older adults and those with renal or hepatic impairment, as slower removal of the drug from the body may increase the risk of toxicity. The medicine is formally restricted from use in patients with pre-existing retinal or visual field changes caused by 4-aminoquinoline compounds.

Overdose and Emergency Response

Roquin (hydroxychloroquine) overdose is a medical emergency that requires immediate intervention, as toxicity can be severe and life-threatening. Symptoms typically manifest rapidly, often within 30 minutes to three hours of ingesting an excessive dose.

Symptoms of Overdose

The acute effects of a Roquin overdose are primarily cardiovascular and neurological. Key signs and symptoms include:

  • Cardiovascular Issues: Life-threatening low blood pressure (hypotension), cardiac conduction abnormalities (e.g., QRS or QTc prolongation), and serious ventricular arrhythmias, which may lead to cardiac arrest.
  • Neurological Effects: Seizures, profound drowsiness or sedation, mental status changes, visual disturbances, and potentially coma.
  • Electrolyte Disturbances: Severe hypokalemia (dangerously low potassium levels in the blood), which can further worsen cardiac toxicity.

When to Seek Help

Call for emergency medical services immediately if you suspect that you or someone else has taken more than the prescribed dose of Roquin, even if no symptoms are present. Do not wait for signs of toxicity to develop. Treatment involves aggressive supportive care, including continuous cardiac monitoring, managing hypotension, correcting electrolyte imbalances, and often administering high-dose diazepam for its protective effect against cardiotoxicity.

Rapid medical attention is crucial, as the severity of the overdose and the window for effective decontamination (such as activated charcoal) are time-sensitive.

Therapeutic Uses of Roquin

What Roquin Treats: Main Uses and Benefits

Roquin (Chloroquine) is a medication used to manage conditions across infectious and chronic autoimmune therapeutic domains. The drug's therapeutic application across its dual uses is considered a relevant component within recognized therapeutic contexts for parasitic and inflammatory disease management.

Treatment and Management of Symptoms

Roquin is applied across therapeutic domains where additional symptomatic support is needed, primarily addressing conditions such as malaria (for treatment and prophylaxis), Systemic Lupus Erythematosus (SLE), active Rheumatoid Arthritis (RA), and Discoid Lupus Erythematosus (DLE). The medication helps manage symptom clusters that may become intense or disruptive, including high fever, chills, joint pain, stiffness, and immune-mediated skin rashes. In clinical scenarios, it is commonly used when short-term symptomatic assistance is needed, or often used during phases when symptoms become more noticeable. The overall therapeutic benefit is that the drug contributes to easing the overall symptom load and supports patients during difficult episodes by easing distress.


Quick Fact: Therapeutic Role in Symptom Management
Roquin is applied in addressing conditions marked by increased physiological stress, and it may assist with symptoms related to inflammatory or irritative states and skin manifestations that interfere with daily functioning. This helps with maintaining functional stability.

Eligibility and Restrictions for Use

Eligibility for Roquin: Official Regulatory Status

Roquin (Chloroquine) is contraindicated and must not be used in patients with a known hypersensitivity to 4-aminoquinoline compounds. Use is also contraindicated for non-acute malaria indications in patients with pre-existing retinal or visual field changes of any cause. The medicine is not recommended for malaria prophylaxis in areas where Chloroquine Resistance is known to occur.

Population Group Official Eligibility Status
Pediatric Patients (Infants/Children) Eligible for malaria treatment and prophylaxis. The regulatory label notes that children are especially sensitive to the drug, with a high risk of fatal accidental ingestion.
Pregnancy Permitted for malaria treatment/suppression when the benefit outweighs the risk, as per public health guidelines. Long-term high-dose use is generally not recommended during Lactation.
Organ Function Caution is mandatory in patients with Hepatic Disease or Alcoholism, and in those with Cardiac Disease or Risk Factors for QT Prolongation (e.g., bradycardia), due to potential for concentration and electrical rhythm effects.
Comorbidities Caution is required for patients with Psoriasis, Porphyria, Epilepsy, or G-6-PD Deficiency (Glucose-6-Phosphate Dehydrogenase) [1.1, 1.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Roquin's official regulatory documentation defines a profile of documented interactions based on both pharmacokinetic and pharmacodynamic effects. Co-administration with certain medicinal products carries restrictions due to documented exposure modification or additive toxicity risks.

The regulatory label mandates avoiding co-administration with substances like Cimetidine, which inhibits metabolism and leads to an increased plasma concentration of Roquin. QT interval prolonging agents are identified for potential additive cardiac risk, and co-administration with Mefloquine is noted for increasing the risk of convulsions.

Pharmacokinetic interference requires mandatory timing rules for certain substances. An interval of at least 4 hours must be observed between Roquin and Antacids and Kaolin to prevent reduced absorption. A 2-hour separation is documented for Ampicillin to address reduced bioavailability.

Roquin's presence can also alter the exposure of co-administered drugs. It may increase serum levels of agents such as Cyclosporine and Digoxin, and it can enhance the hypoglycemic effect of antidiabetic medications. Furthermore, Roquin may increase the exposure of drugs metabolized by CYP2D6. Caution is officially documented for use in patients with hepatic disease or impaired renal function due to alterations in drug clearance.

Mechanism of Action

How Roquin Works

Roquin (Chloroquine) initiates its action as an amphiphilic weak base, a property that causes it to diffuse into and concentrate within acidic organelles, such as the Plasmodium digestive vacuole and host immune cell endosomes and lysosomes. This accumulation raises the internal pH of these compartments, which disrupts their acid-dependent functions.

Cascade 1: Termination of Parasitic Detoxification

In the parasite, the pH increase and direct drug action inhibit the enzyme Heme Polymerase, preventing the detoxification of toxic Heme (Ferriprotoporphyrin IX). The resulting buildup of Heme inside the digestive vacuole induces oxidative stress and membrane damage, which ultimately results in parasite cell lysis.

Cascade 2: Suppression of Inflammatory Signaling

In host immune cells, the same core mechanism suppresses the processing of cellular antigens and blocks endosomal Toll-like Receptors (TLR7/TLR9). These actions limit the downstream production and systemic release of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), which leads to a reduction in pro-inflammatory signaling along those pathways.

Dosage and Administration Information

How Roquin is Used: Official Administration Guidelines

Roquin (Chloroquine) is an oral medication supplied as a tablet, and its usage pattern is defined by established guidelines that differ based on the specific application.

Administration and Dosage Regimens

Official dosing is often specified in terms of Chloroquine Base, not the Chloroquine Phosphate salt, which requires proper calculation for accurate administration (e.g., 500 mg salt equals 300 mg base).

Usage Context Frequency and Duration Pattern Standard Adult Dose (Base)
Malaria Prophylaxis 300 mg once weekly, starting before and continuing for 4 to 8 weeks after exposure 300 mg base
Acute Malaria Treatment Total 1.5 g base over 3 days, beginning with a higher loading dose followed by maintenance doses 600 mg initial dose
RA/Lupus Maintenance Typically once 150 mg base daily for long-term use 150 mg base

Procedural and Population Rules

Frequency and Timing: The frequency of use is defined by the condition being addressed, ranging from a once-weekly schedule for prevention to a once-daily schedule for chronic maintenance. For prophylaxis, the tablet is intended to be taken on the same day each week.

Special Conditions: Official administration instructions require separation from certain concurrent medications, such as antacids or Kaolin, by at least 4 hours to avoid interference with the drug's absorption.

Pediatric Use: The dose for children is calculated strictly based on body weight (mg base/kg) and must under no circumstances exceed the maximum adult dose, regardless of the child's weight. Use in patients with hepatic or renal impairment requires caution and close monitoring.

Recent Clinical Evidence

Research evidence / Overview of Studies for Roquin

Evidence for Use in Malaria (Treatment and Prophylaxis)

Research for Roquin as an antimalarial includes short-term Randomized Controlled Trials (RCTs) and field studies that examined the clearance of fever and parasites in susceptible infections. Studies reported measurements of a rapid clearance of the parasite, contributing to the historical understanding of its role. However, evidence for acute use against the most common malaria species (P. falciparum) is now severely limited globally. This is because widespread drug resistance has developed; findings indicate that this has led to therapeutic failure in many regions, restricting its current utility.


Evidence for Use in Chronic Autoimmune Conditions

For Systemic Lupus Erythematosus (SLE), studies include long-term RCTs and extensive observational cohort studies. Researchers explored outcomes such as changes in disease activity scores, the frequency of disease flare-ups, and the accumulation of long-term organ damage. Research reports observations related to damage accrual measurements in patient groups with prolonged use, and studies describe patterns of disease stability.

For Rheumatoid Arthritis (RA) and Discoid Lupus Erythematosus (DLE), the evidence base includes medium-term RCTs and smaller observational studies. Researchers examined outcomes related to clinical response criteria (e.g., ACR scores) for RA and changes in skin lesion measurements for DLE, positioning Roquin as a standard therapeutic option for milder disease or skin-limited conditions.


Research Gaps, Long-Term Patterns, and Specific Populations

Long-term follow-up allows researchers to study complex outcomes, such as whether continuous use may be associated with patterns related to long-term organ damage accrual in SLE. Data for certain groups, such as patients with complex concurrent health conditions, remain insufficient. A primary limitation is that much of the highest-quality recent evidence relies on its derivative, hydroxychloroquine, requiring careful inference for Roquin itself. Furthermore, efficacy in malaria is highly restricted by global patterns of drug resistance, and research is ongoing to address these uncertainties.

Frequently Asked Questions (FAQ)

Common questions about Roquin (FAQ)


Q: How quickly does Roquin typically start to work?

A: Studies on this drug class indicate that its action is cumulative, which means its full effects are not immediate. This indicates that for chronic conditions, the full therapeutic effect may not be observed immediately. Official data reports that the maximum therapeutic benefit for these uses is typically observed after treatment has continued for weeks to months.


Q: Does Roquin affect fertility in men or women?

A: Official information derived from animal studies suggests that Roquin may have effects on reproductive organs. Specifically, high doses administered to male rats showed a decrease in testosterone levels and reproductive organ weights. Information regarding human fertility effects for this drug class is limited and complex.


Q: Is there a generic version of Roquin available?

A: Yes, the active ingredient in Roquin, which is chloroquine phosphate, is available as a generic medicine. The generic form shares the same active chemical compound as the branded drug. The availability of the generic form allows for various prescribing options.


Q: Are there any dietary restrictions or foods to avoid while taking Roquin?

A: Official guidance mentions that the consumption of grapefruit or grapefruit juice should be limited while taking this medication. Official guidance notes that this caution is related to grapefruit’s potential to increase the drug’s concentration in the bloodstream. No other general dietary restrictions are widely noted in the official regulatory documents.


Q: Can Roquin change my mood or cause anxiety?

A: Official safety labeling indicates that neuropsychiatric reactions are a potential concern with this drug class. Reports have described effects on the central nervous system, and in rare instances, serious events such as suicidal behavior have been documented.


Q: If I am taking Roquin, can I still get vaccinations?

A: Regulatory information indicates that Roquin, when taken for malaria prevention, can reduce the antibody response to primary immunization with the human diploid-cell rabies vaccine. Official documentation notes caution regarding concurrent use with certain live vaccines.


Q: What happens if I stop taking Roquin suddenly?

A: For chronic conditions like lupus or rheumatoid arthritis, regulatory data notes that discontinuing this medication may lead to a worsening of the underlying condition or an increased risk of disease flares. Any changes to a treatment regimen should be discussed with the prescribing professional.


Q: Is alcohol consumption restricted while using Roquin?

A: The official product information states that caution is required when Roquin is used in patients with alcoholism or pre-existing hepatic disease (liver impairment). This is because the drug is concentrated and metabolized by the liver. The official warning emphasizes potential risks in individuals with liver impairment.


Q: Does Roquin have a warning about driving or operating machinery?

A: Due to the potential for adverse effects on the nervous system, caution is generally noted regarding activities that require alertness, such as driving or operating heavy machinery. Official information advises that patients be aware of the effects of the medicine before engaging in such tasks.


Q: What is the purpose of the patient information leaflet that comes with Roquin?

A: The Patient Information Leaflet, also known as a Medication Guide, is a regulatory document required for this drug. Its purpose is to officially communicate the essential information needed for the safe and effective use of the drug. It outlines the associated benefits, risks, and required precautions in clear language.


Q: Does Roquin interact with herbal teas or natural remedies?

A: Regulatory labels specify interactions with non-drug substances that affect drug absorption, such as kaolin (a mineral sometimes found in supplements or remedies). While a general statement for all herbal teas is not provided, caution is advised for any product that might affect the body's absorption or processing of the medicine.


Q: Is it required to take Roquin with a meal?

A: While the Roquin label does not always explicitly require administration with food, instructions for related antimalarial compounds often advise administration with a meal or milk. This practice is often noted to potentially help reduce the possibility of stomach upset or digestive discomfort.


Q: Why is Roquin sometimes prescribed off-label (for non-approved uses)?

A: Governmental bodies have acknowledged the use of Roquin outside its originally approved indications for malaria and rheumatic diseases. This is typically related to its established immunomodulatory action—its known ability to affect the body’s immune response—which may be relevant to other conditions.

How should Roquin be stored and disposed of?

Storage Requirements

Roquin (Chloroquine Phosphate) tablets must be stored at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F), with limited excursions permitted to 30 C (86 F). The product must be protected from light, excess heat, and moisture, and must be kept from freezing.

Storage Classification Details
Temperature Range 20 C to 25 C (Controlled Room Temp.)
Container Rule Dispense in a tight, light-resistant container with a child-resistant closure.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Roquin tablets should be disposed of via a drug take-back program or an authorized collection site. If a take-back option is unavailable, the medication is not on the FDA flush list and should be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed container before being thrown into household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Roquin found in:

A-Z Index: